Illumina (NASDAQ: ILMN) got marketing authorization from the U.S. Food and Drug Administration for its diagnostic devices for next generation gene sequencing or NGS. Two of the devices focus on a gene associated with cystic fibrosis. More than 10 million people carry the cystic fibrosis transmembrane conductance regulator gene, according to an FDA statement.
The diagnostic will screen for a wide number of variations in the CFTCR gene, Elizabeth Mansfield, director of personalized medicine in the FDA’s medical-device center, told The Wall Street Journal.
The FDA also granted the company’s DeNovo petition for its MiSeqDx Universal Kit. The kit is designed to help clinical labs develop their own diagnostic tests on an in vitro diagnostic platform. The DeNovo petition approval means that the classification changes from a Class 3 to a Class 2 or Class 1 device.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A New England Journal of Medicine editorial sought to put the FDA’s move in perspective:
“Clinicians can selectively look for an almost unlimited number of genetic changes that may be of medical significance. Access to these data opens the door for the transformation of research, clinical care, and patient engagement.”
Cystic fibrosis can affect the lungs, pancreas, liver, intestines and other organs. It affects people who inherit the gene from both parents. More than 10 million people in the U.S. are cystic fibrosis carriers, while about 30,000 children and adults have the condition. The life expectancy for people with cystic fibrosis is 37 years.
There’s currently no cure for cystic fibrosis. What makes the FDA’s move to green-light the devices significant is it will provide a way for parents to find out if they both carry the gene. It could also help people get a diagnosis earlier.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Alberto Gutierrez, the director of the FDA’s Office of In Vitro Diagnostics and Radiological Health, said: “Before NGS, sequencing genes associated with a particular disease was a long and costly process. Today, we have the capability to read and interpret large segments of DNA very quickly in a single test and this information-rich technology is becoming more accessible for use by physicians in the care of their patients.”
The next generation sequencing market is projected to grow to $7.6 billion by 2018, according to BCC Research.
